B-Cell Lymphoma Cells Overexpressing BMI-1 Are Correlated with Drug Resistance through Enhanced Expression of Survivin and Are Effectively Eliminated by T Cells with Anti-CD38 Chimeric Receptor

被引：0
|
作者：
Bhattacharyya, Joyeeta [1 ]
Mihara, Keichiro [1 ]
Ohtsubo, Motoaki [2 ]
Yasunaga, Shin'ichiro [2 ]
Takihara, Yoshihiro [2 ]
Hoshi, Masaharu [3 ]
Kimura, Akiro [1 ]
机构：
[1] Hiroshima Univ, Dept Hematol & Oncol, Res Inst Radiat Biol & Med, Hiroshima, Japan
[2] Hiroshima Univ, Dept Stem Cell Biol, Res Inst Radiat Biol & Med, Hiroshima, Japan
[3] Hiroshima Univ, Dept Radiat Biophys, Res Inst Radiat Biol & Med, Hiroshima, Japan
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1488 / 1488
页数：1
相关论文
共 50 条
  • [31] How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?
    de Ramon Ortiz, Carmen
    Wang, Sisi
    Stathis, Anastasios
    Bertoni, Francesco
    Zenz, Thorsten
    Novak, Urban
    Simonetta, Federico
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
  • [32] Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor
    Kochenderfer, James N.
    Dudley, Mark E.
    Kassim, Sadik H.
    Carpenter, Robert O.
    Yang, James C.
    Phan, Giao Q.
    Hughes, Marybeth S.
    Sherry, Richard M.
    Feldman, Steven
    Spaner, David
    Nathan, Debbie-Ann N.
    Morton, Kathleen E.
    Toomey, Mary Ann
    Rosenberg, Steven A.
    BLOOD, 2013, 122 (21)
  • [33] Efficacy of CD19-targeted chimeric antigen receptor T cells in the treatment of relapsed extramedullary B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL).
    Hu, Yongxian
    Wu, Zhao
    Yu, Jian
    Wang, Jiasheng
    Wei, Guoqing
    Wu, Wenjun
    Luo, Yi
    Shi, Jimin
    Xiao, Lei
    Huang, He
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for Adult Patients with Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia
    Huang, Liang
    Wang, Na
    Li, Chunrui
    Cao, Yang
    Xiao, Yi
    Xiao, Min
    Zhang, Yicheng
    Zhang, Tongcun
    Zhou, Jianfeng
    BLOOD, 2017, 130
  • [35] Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials
    Zhu, Yangmin
    Tan, Youping
    Ou, Ruiming
    Zhong, Qi
    Zheng, Liling
    Du, Yuanyuan
    Zhang, Qing
    Huang, Jing
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 96 (04) : 389 - 396
  • [36] Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models
    Ruella, Marco
    Maude, Shannon L.
    Engels, Boris
    Barrett, David M.
    Frey, Noelle
    Marcucci, Katherine T.
    Shestova, Olga
    Singh, Nathan
    Perazzelli, Jessica
    Christian, David A.
    Haagen, Dana
    Lacey, Simon F.
    Melenhorst, J. Joseph
    Brogdon, Jennifer
    Young, Regina M.
    Porter, David L.
    June, Carl H.
    Grupp, Stephan A.
    Gill, Saar I.
    BLOOD, 2017, 130
  • [37] Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells (vol 30, pg 497, 2019)
    Xu, Xu
    HUMAN GENE THERAPY, 2022, 33 (5-6) : 346 - 346
  • [38] Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms
    M Ruella
    S S Kenderian
    O Shestova
    M Klichinsky
    J J Melenhorst
    M A Wasik
    S F Lacey
    C H June
    S Gill
    Leukemia, 2017, 31 : 246 - 248
  • [39] Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms
    Ruella, M.
    Kenderian, S. S.
    Shestova, O.
    Klichinsky, M.
    Melenhorst, J. J.
    Wasik, M. A.
    Lacey, S. F.
    June, C. H.
    Gill, S.
    LEUKEMIA, 2017, 31 (01) : 246 - 248
  • [40] CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma
    Liu, Hui
    Lei, Wen
    Zhang, Chaoting
    Yang, Chunmei
    Wei, Juying
    Guo, Qunyi
    Guo, Xiaojun
    Chen, Zhilu
    Lu, Ying
    Young, Ken H.
    Lu, Zheming
    Qian, Wenbin
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 473 - 484
12345